Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.01 USD | +0.83% | -1.31% | -9.88% |
Mar. 22 | Gilead Sciences Completes $4.3 Billion Cymabay Acquisition | MT |
Mar. 22 | Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc.. | CI |
Financials (USD)
Sales 2024 * | 27.51B | Sales 2025 * | 28.03B | Capitalization | 90.95B |
---|---|---|---|---|---|
Net income 2024 * | 6.54B | Net income 2025 * | 6.86B | EV / Sales 2024 * | 3.74 x |
Net Debt 2024 * | 11.84B | Net Debt 2025 * | 4.96B | EV / Sales 2025 * | 3.42 x |
P/E ratio 2024 * |
14
x | P/E ratio 2025 * |
13.2
x | Employees | 18,000 |
Yield 2024 * |
4.3% | Yield 2025 * |
4.48% | Free-Float | 99.86% |
Latest transcript on Gilead Sciences, Inc.
1 day | +0.83% | ||
1 week | -1.31% | ||
Current month | +1.26% | ||
1 month | -0.01% | ||
3 months | -9.16% | ||
6 months | -3.36% | ||
Current year | -9.88% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.99% | 227 M€ | +6.90% | - | |
8.10% | 0 M€ | 0.00% | - | |
8.06% | 0 M€ | 0.00% | - | |
5.23% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 73.01 | +0.83% | 7,747,590 |
24-03-26 | 72.41 | -0.23% | 5,362,890 |
24-03-25 | 72.58 | -0.04% | 5,543,898 |
24-03-22 | 72.61 | -0.66% | 7,730,620 |
24-03-21 | 73.09 | -1.20% | 5,836,856 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.88% | 90.95B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.11% | 210B | |
+1.34% | 210B | |
-7.26% | 201B | |
-3.51% | 157B |